TABLE 4.
Dosing regimend | Breakpoint (%)
|
||
---|---|---|---|
1/19 mg/litera | 2/38 mg/literb | 3/57 mg/literc | |
TMP | |||
160 mg q12h | 3 | <0.1 | <0.1 |
160 mg q8h | 36 | 0.2 | 0.1 |
320 mg q12h | 81 | 3 | 0.2 |
320 mg q8h | 100 | 36 | 3 |
Weight based | 100 | 31 | 0.6 |
SMX | |||
800 mg q12h | 98 | 7 | 0.2 |
800 mg q8h | 100 | 66 | 7 |
1,600 mg q12h | 100 | 98 | 42 |
1,600 mg q8h | 100 | 100 | 98 |
Weight based | 100 | 100 | 98 |
1 (TMP)/19 (SMX) mg/liter represents the MIC90 for Australian isolates.
2/38 mg/liter represents the susceptibility threshold.
3/57 mg/liter represents the MIC90 for Thai isolates.
Weight-based dosing for patients was as follows: <40 kg (body weight), 160/800 mg q12h; 40 to 60 kg, 240/1,200 mg q12h; and >60 kg, 320/1,600 mg q12h.